Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5…
SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to…